JCV neutralizing antibodies

Abstract

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.

What is claimed is: 
     
       1. An isolated monoclonal antibody comprising:
 a heavy chain variable domain comprising a CDR1 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:31, a CDR2 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:35, and a CDR3 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:9; and 
 a light chain variable domain comprising a CDR1 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:17, a CDR2 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:3, and a CDR3 amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:4. 
 
     
     
       2. The isolated monoclonal antibody of  claim 1 , wherein at least one framework region amino acid sequence of the heavy chain variable domain is at least 90% identical to at least one corresponding framework region amino acid sequence of a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20. 
     
     
       3. The isolated monoclonal antibody of  claim 1 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:20. 
     
     
       4. The isolated monoclonal antibody of  claim 3 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20. 
     
     
       5. The isolated monoclonal antibody of  claim 1 , wherein at least one framework region amino acid sequence of the light chain variable domain is at least 90% identical to at least one corresponding framework region amino acid sequence of a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 
     
     
       6. The isolated monoclonal antibody of  claim 1 , wherein the isolated monoclonal antibody comprises a light chain variable domain amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:15. 
     
     
       7. The isolated monoclonal antibody of  claim 6 , wherein the isolated monoclonal antibody comprises a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 
     
     
       8. The isolated monoclonal antibody of  claim 1 , wherein the isolated monoclonal antibody comprises a heavy chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:15. 
     
     
       9. The isolated monoclonal antibody of  claim 1 , wherein the isolated monoclonal antibody is an isolated chimeric monoclonal antibody. 
     
     
       10. The isolated monoclonal antibody of  claim 1 , wherein the isolated monoclonal antibody comprises an IgG1 Fc-region. 
     
     
       11. The isolated monoclonal antibody of  claim 8 , wherein the isolated monoclonal antibody is an isolated chimeric monoclonal antibody. 
     
     
       12. The isolated monoclonal antibody of  claim 8 , wherein the isolated monoclonal antibody comprises an IgG1 Fc-region.